Summary

Your GC result determines how much vitamin D binding protein you produce — TT carriers have genetically lower circulating 25(OH)D levels, but the critical nuance is that your bioavailable vitamin D may be adequate even when your blood test looks deficient, so don't blindly chase a number.

Genotype spectrum

GG (normal transport)

Your blood test results are straightforward to interpret. Standard 25(OH)D targets (30-50 ng/mL) apply directly.

GT (reduced transport)

Your blood test runs slightly low, but your functional vitamin D status is better than the number suggests. You're less likely to be genuinely deficient than your blood test implies.

TT (low transport)

Your blood test requires genetic context to interpret correctly. This is genuinely valuable information.

Practical takeaway

For TT Carriers (Low DBP — Informed Interpretation Required)

Blood test interpretation:
• 25(OH)D below 15 ng/mL: Likely genuinely deficient even for you. Supplement 2000-4000 IU/day vitamin D3. Retest in 2-3 months.
• 25(OH)D 15-25 ng/mL: Your "grey zone." This may represent adequacy for you. If asymptomatic, moderate supplementation (1000-2000 IU/day) is reasonable. If symptomatic, treat as deficient.
• 25(OH)D 25-35 ng/mL: Likely adequate for you. Standard maintenance (1000 IU/day or regular sun exposure).
• Above 35 ng/mL: Sufficient. No supplementation needed unless for specific clinical indication.

Do not chase 50+ ng/mL. Some wellness advice targets 50-80 ng/mL for "optimal" health. For GG carriers, this is debatable but harmless at standard supplementation doses. For TT carriers, pushing total 25(OH)D to these levels requires disproportionately high supplementation that may not add bioavailable vitamin D.

Supplementation when appropriate:
• Vitamin D3 (cholecalciferol), not D2. Take with fat-containing meal.
• 1000-2000 IU/day for maintenance. 2000-4000 IU/day if genuinely deficient.
• Vitamin K2 (MK-7): 100-200 mcg/day. Important alongside any vitamin D supplementation to direct calcium to bone.
• Test after 2-3 months of supplementation. Expect your levels to rise less dramatically than GG carriers at the same dose — this is expected, not a sign that supplementation isn't working.

Latitude and season awareness:
• If you live above 40°N (Northern US, UK, Northern Europe, Canada): vitamin D synthesis from sun is negligible November-March. Supplementation during winter months is more important.
• If you live in a sunny climate with regular sun exposure: you may need no supplementation at all, despite a blood test that reads "low."

If your doctor says "your vitamin D is low":
• This is a conversation worth having. Most doctors use standard cutoffs without considering GC genotype.
• You don't need to push back on supplementation — moderate supplementation (1000-2000 IU/day) is safe and may provide benefit.
• But you can avoid aggressive high-dose protocols (50,000 IU weekly loading doses) that are designed for genuinely deficient patients and may be un

Evidence detail

What This Gene Does

GC encodes vitamin D binding protein (DBP, also called Gc-globulin), the primary transport protein for vitamin D metabolites in the blood. DBP carries approximately 85-90% of circulating 25(OH)D (the form measured in standard blood tests) and 85% of 1,25(OH)₂D (the active form). Only the unbound "free" fraction and the loosely albumin-bound fraction are considered bioavailable — meaning they can actually enter cells and interact with VDR.

The rs2282679 variant affects DBP production levels. Lower DBP means less total 25(OH)D in circulation (because there's less carrier protein), but it also means a larger proportion of the vitamin D that IS circulating is bioavailable. This creates a paradox: your blood test may read "insufficient" while your cells are actually receiving adequate vitamin D. Understanding this distinction is the difference between appropriate intervention and unnecessary mega-dosing.

Mechanism

Vitamin D transport and the DBP system work like this:

1. 25(OH)D is produced in the liver from vitamin D3 (from sun or supplements) and enters the bloodstream.
2. DBP (vitamin D binding protein), encoded by GC, binds approximately 85-90% of circulating 25(OH)D. Albumin loosely binds another ~10-15%. Only ~0.03% circulates freely.
3. Standard 25(OH)D blood tests measure TOTAL 25(OH)D — bound + free. This total is used to define deficiency (<20 ng/mL), insufficiency (20-30 ng/mL), and sufficiency (>30 ng/mL).
4. Bioavailable 25(OH)D = free + albumin-bound fractions. These can cross cell membranes and activate VDR. DBP-bound vitamin D requires megalin receptor-mediated endocytosis to enter cells — a different, tissue-specific pathway.

What rs2282679 does:

The T allele is associated with lower GC gene expression, producing less DBP protein. Less DBP means:
• Less total 25(OH)D in blood — fewer carrier proteins → less vitamin D circulating in bound form → lower total measurement.
• Higher bioavailable fraction — same or similar free vitamin D, but it represents a larger percentage of the lower total.
• Potentially adequate vitamin D signalling despite a "low" blood test — because the cells can access the free fraction directly.

The measurement paradox:

Standard 25(OH)D cutoffs (30 ng/mL for sufficiency) were derived from populations with average DBP levels. For TT carriers with genetically low DBP, these cutoffs systematically overdiagnose deficiency. A TT carrier at 22 ng/mL may have the same bioavailable vitamin D as a GG carrier at 32 ng/mL. Applying the same cutoff to both leads to unnecessary treatment of the TT carrier.

What this does NOT mean:

This does not mean TT carriers can ignore vitamin D entirely. Genuine deficiency still occurs. Sun avoidance, northern latitude, dark skin, obesity, and malabsorption all reduce vitamin D supply regardless of genotype. The GC genotype modifies the interpretation of your blood test — it doesn't guarantee adequacy. If you have symptoms of deficiency (bone pain, muscle weakness, frequent illness, fatigue) and low 25(OH)D, treatment is appropriate.

GC Vitamin D Binding

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (6)